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Background
KS is a disease of multifocal vascular proliferation.
Matrix metalloproteinases (MMPs) and type I collagen
play critical roles in angiogenesis and are potential
targets. Halofuginone (Tempostatin™), a synthetic quina-
zolinone alkaloid derivative, induced anti-angiogenic,
anti-metastatic and anti-proliferative effects in preclini-
cal studies. It inhibits several essential stages of angio-
genesis: endothelial cell proliferation, MMP2 expression,
BM invasion, ECM deposition by newly formed vessels,
synthesis of type I collagen during angiogenic sprouting,
and bFGF-induced neovascularization. These data
suggested that halofuginone might have activity in KS.
Methods
The AMC developed a novel trial design with a blinded
intra-patient vehicle control. Halofuginone was supplied
by Collgard Biopharmaceuticals Ltd (Atlanta, GA) to the
NCI-DCTD under a CRADA as a 0.01% w/w ointment.
Twelve KS lesions were divided into two groups of six,
designated Group A and Group B. Tubes designated A
and B containing either halofuginone or matching placebo
ointment were supplied in a blinded fashion. Ointment A
was applied to Group A lesions and ointment B to Group
B lesions twice daily. Lesion response was assessed every
4 weeks for Group A and Group B lesions individually,
and global response assessed both treated and untreated
disease. Tumor biopsies obtained at baseline and from
both Group A and B lesions during treatment were stu-
died for expression of type I collagen by ISH and of
MMP2 and VEGF by IHC. A patient subset had blood
sampling after 8 weeks to evaluate systemic absorption.
Results
Twenty-three patients were treated. Median CD4 count
was 322 (2-693); 68% had undetectable HIV RNA. Treat-
ment was well tolerated. Of 14 patients who completed
12 weeks of treatment, 26% (95% CI, 10%-48%) showed
partial response in halofuginone-treated lesions and 17%
in placebo-treated lesions (95% CI, 5%-39%), (P=0.689).
Global response was 30% (95% CI, 13%-53%). None of
10 subjects showed detectable blood levels. Type 1 col-
lagen message decreased significantly in halofuginone-
treated lesions at week 4, whereas vehicle-treated lesions
showed no change. VEGF protein expression decreased
significantly in vehicle-treated lesions at week 4, whereas
halofuginone-treated lesions showed no change. There
were no differences in levels of MMP2 or VEGF protein
between halofuginone- and vehicle-treated lesions.
No changes in HIV RNA levels or CD4 counts were
observed.
Conclusion
Although topical halofuginone appears ineffective for KS
treatment, this study presents a novel design that could
be applied to future studies using the patient as his own
control to test a topical, non-absorbed agent.
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